Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: A case report

Oncology Letters
Kazue ShiozawaYasukiyo Sumino

Abstract

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-associated mortality worldwide. No effective treatment has been established for unresectable advanced HCC, and the prognosis is poor. Sorafenib is an oral multi-targeted tyrosine kinase inhibitor for unresectable advanced HCC that significantly improves progression-free and overall survival. However, in the two large phase III clinical trials (the SHARP and Asia-Pacific trials), no cases of complete response (CR) were reported. The present study reports the case of a 68-year-old male with hepatitis C virus-related cirrhosis and multiple recurrent HCCs, with a tumor thrombus of the third portal vein following resection. The patient received 400 mg once daily (half the standard dose) of sorafenib for two years and achieved a CR. At the most recent follow-up examination at one year after the cessation of treatment, the patient was observed to be in remission without clinical or imaging evidence of disease recurrence.

References

Mar 12, 2005·CA: a Cancer Journal for Clinicians·D Max ParkinPaola Pisani
Oct 4, 2006·Nature Reviews. Drug Discovery·Scott WilhelmSusan Kelley
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Sep 8, 2010·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Alexandre Chan, Eng Hooi Tan
Jan 19, 2011·BMC Gastroenterology·Rodolfo SaccoCarlo Bartolozzi
Nov 17, 2012·World Journal of Gastroenterology : WJG·Kazue ShiozawaYasukiyo Sumino

❮ Previous
Next ❯

Citations

Mar 18, 2016·Cancer Biotherapy & Radiopharmaceuticals·Dario LorenzinAndrea Risaliti
Jul 7, 2015·Journal of Digestive Diseases·Ahmad Najib AzmiKhean-Lee Goh
Nov 30, 2016·World Journal of Gastroenterology : WJG·Michitoshi TakanoHirohiko Sakamoto

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Software Mentioned

mRECIST

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.